Table 1 Patient demographics and tumor characteristics
All Disease | |||
|---|---|---|---|
APBI | WBI | P value | |
Patients | 202 | 94 | |
Months Follow-up | 64.3 | 64.1 | 0.422 |
(Range) | (2.2-96.6) | (4.4-98.4) | |
Median Age | 60.0 | 56.9 | 0.087 |
(Range) | (34.7-84.3) | (33.0-83.2) | |
Race | < 0.001* | ||
Caucasian | 169 (83.7%) | 52 (55.3%) | |
Black | 31 (15.4%) | 42 (44.7%) | |
Other | 2 (1.0%) | 0 (0%) | |
Anatomy | |||
Side | 0.803 | ||
Right | 97 (48.0%) | 47 (50.0%) | |
Left | 105 (52.0%) | 47 (50.0%) | |
Quadrant | |||
UOQ | 88 (43.6%) | 64 (68.1%) | < 0.001* |
UIQ | 53 (26.2%) | 17 (18.1%) | |
LIQ | 29 (14.4%) | 5 (5.3%) | |
LOQ | 32 (15.8%) | 8 (8.5%) | |
Grade | 0.207 | ||
DCIS | 40 (19.8%) | 18 (19.1%) | |
I | 78 (38.6%) | 25 (26.6%) | |
II | 55 (27.2%) | 27 (28.7%) | |
III | 29 (14.4%) | 20 (21.3%) | |
Unknown | 0 (0%) | 4 (4.3%) | |
Stage | |||
Tis | 40 (19.8%) | 18 (19.1%) | |
T1 mic | 3 (1.5%) | 4 (4.3%) | |
T1 a | 23 (11.4%) | 7 (7.4%) | |
T1 b | 67 (33.2%) | 29 (30.9%) | |
T1 c | 54 (26.7%) | 31 (33.0%) | |
T1 | 147 (72.8%) | 71 (75.5%) | |
T2 | 15 (7.4%) | 5 (5.3%) | |
Histology | 0.092 | ||
DCIS | 40 (19.8%) | 18 (19.1%) | |
Invasive Ductal | 141 (69.8%) | 60 (63.8%) | |
Invasive Lobular | 8 (4.0%) | 11 (11.7%) | |
Invasive Tubular | 7 (3.5%) | 1 (1.1%) | |
Invasive Mucinous | 5 (2.5%) | 2 (2.1%) | |
Invasive Papillary | 1 (0.5%) | 2 (2.1%) | |
Estrogen Receptor | 0.464 | ||
ER + | 167 (82.7%) | 71 (71.6%) | |
ER - | 26 (12.9%) | 15 (16.0%) | |
ER Unknown | 9 (4.5%) | 8 (8.5%) | |
Progesterone Receptor | 0.489 | ||
PR + | 134 (66.3%) | 56 (59.6%) | |
PR - | 59 (29.2%) | 30 (31.9%) | |
PR Unknown | 9 (4.5%) | 8 (8.5%) | |
Her-2/Neu (Invasive Only) | 0.350 | ||
Overexpressed | 14 (6.9%) | 9 (4.5%) | |
Not Overexpressed | 147 (72.8%) | 62 (66.0%) | |
Unknown | 41 (20.3%) | 23 (24.5%) | |
Disease Type | |||
Luminal A | 128 (63.4%) | 51 (54.3%) | 0.353 |
Luminal B | 9 (4.5%) | 7 (7.5%) | |
Her-2/Neu | 5 (2.5%) | 2 (2.1%) | |
Basal | 16 (7.9%) | 11 (3.7%) | |
DCIS | 40 (19.8%) | 18 (6.1%) | |
Unable to classify | 4 (2.0%) | 5 (5.3%) | |
LVSI (Invasive Only) | 0.591 | ||
Present | 10 (4.9%) | 6 (8.1%) | |
Absent | 152 (74.5%) | 70 (91.9%) | |
LCIS | 0.011* | ||
Present | 15 (7.4%) | 17 (18.1%) | |
Absent | 187 (92.6%) | 77 (81.9%) | |
EIC (Invasive Only) | 0.688 | ||
Present | 4 (2.5%) | 3 (3.9%) | |
Absent | 148 (91.4%) | 73 (96.1%) | |
Unknown | 10 (6.2%) | 0 (0%) | |
Endocrine Therapy (Invasive Only) | 0.182 | ||
Given | 127 (78.4%) | 50 (65.8%) | |
Not Given | 34 (21.0%) | 21 (27.6%) | |
Unknown | 1 (0.6%) | 5 (6.6%) | |
Endocrine Therapy (DCIS Only) | 0.756 | ||
Given | 29 (72.5%) | 14 (77.8%) | |
Not Given | 11 (27.5%) | 4 (22.2%) | |
Unknown | 0 (0%) | 0 (0%) | |
Cytotoxic Chemotherapy (Invasive Only) | 0.102 | ||
Given | 35 (21.6%) | 23 (30.3%) | |
Not Given | 127 (78.4%) | 49 (64.5%) | |
Unknown | 0 (0%) | 4 (5.3%) |